RECQL and glioblastoma: Observed sensitivity of RECQ1-depleted cells to DNA alkylating agents is consistent with a newly identified role of RECQ1 in BER [31] and a previous study where glioblastoma cells depleted of RECQ1 were found to be more sensitive to TMZ treatment [62].